Evidence map›Paper›PMID 30652417›Full record

ArticleCancer medicine2019

Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer.

Sung Jun Ma, Gregory M Hermann, Kavitha M Prezzano, Lucas M Serra, Austin J Iovoli, Anurag K Singh

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04737551 (Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04737551 unknown statusnot on this mapstarted 2020, after this paper: background citation

Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study

Typeobservational_patient_registrySponsorShanghai Zhongshan HospitalRan2020 to 2023Enrolled400ConditionsResectable Pancreatic Cancer, Adjuvant Chemoradiotherapy, SurgeryArmsFollow-up only, Adjuvant chemotherapy, Adjuvant chemoradiotherapy, Adjuvant chemoradiotherapy + Adjuvant chemotherapy
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sung Jun MaDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-0838-3996
Gregory M HermannDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0003-3386-8546
Kavitha M PrezzanoDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-6702-3384
Lucas M SerraJacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York.ORCID 0000-0002-2104-0568
Austin J IovoliJacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York.
Anurag K SinghDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-6703-5115
Roswell Park Comprehensive Cancer Center · USUniversity at Buffalo, State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis National Cancer Database (NCDB) analysis evaluates the clinical outcomes of postoperative chemotherapy followed by concurrent chemoradiation (C + CRT) compared to concurrent chemoradiation (CRT) alone or adjuvant chemotherapy alone (C) for resected pancreatic cancer.

methodsThe NCDB was queried for primary stage I-II, cT1-3N0-1M0, resected pancreatic adenocarcinoma treated with adjuvant C, CRT, or C + CRT (2004-2015). Patients treated with C + CRT were compared with those treated with C (cohort C) and CRT (cohort CRT). Baseline patient, tumor, and treatment characteristics were examined. Kaplan-Meier analysis, multivariable Cox proportional hazards method, forest plot, and propensity score matching were used.

resultsAmong 5667 patients, median follow-up was 34.7, 45.2, and 39.7 months for the C, CRT, and C + CRT cohorts, respectively. By multivariable analysis for all patients, C and CRT had worse OS compared to C + CRT. Treatment interactions were seen among pathologically node-positive disease. C + CRT was favored in 1-3 and 4+ positive lymph node diseases when compared to C or CRT alone, but none of the treatment options were significantly favored in node negative disease. Using propensity score matching, 2152 patients for cohort C and 1774 patients for cohort CRT were matched. C + CRT remained significant for improved OS for both cohort C (median OS 23.3 vs 20.0 months) and cohort CRT (median OS 23.4 vs 20.8 months).

conclusionThis NCDB study using propensity score matched analysis suggests an OS benefit for C + CRT compared to C or CRT alone following surgical resection of pancreatic cancer, particularly for patients with pathologically positive lymph nodes.

Indexed as

AgedChemoradiotherapyChemotherapy, AdjuvantCohort StudiesFemaleHumansMaleNeoplasm StagingPancreatic NeoplasmsSurvival RateTreatment Outcomeadjuvant chemoradiationadjuvant chemotherapyadjuvant radiationadjuvant therapyNational Cancer Databaseresectable pancreatic cancer

Identifiers

PMID30652417
PMCPMC6434497
OpenAlexW2908583255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.